From Practice Update, an oncology journal updater that I subscribe to.
The Natural History of Primary Myelofibrosis and RuxolitinibBlood 2014 Jan 17;[EPub Ahead of Print], F Passamonti, M Maffioli, F Cervantes, A Vannucchi, E Morra, T Barbui, D Caramazza, L Pieri, E Rumi, H Gisslinger, L Knoops, J-J Kiladjian, B Mora, N Hollander, C Pascutto, C Harrison, M Cazzola
Research · January 27, 2014
Take Home message from Chris Tully, MD.
- Analyzing patient outcomes from the COMFORT-2 study (comparing ruxolitinib with best available therapy for patients with primary myelofibrosis) and comparing them with outcomes in the cohort of patients with primary myelofibrosis used to develop the dynamic International Prognostic Scoring System (IPSS), it was determined that patients receiving ruxolitinib had a median OS of 5 years compared with 3.5 years in the comparator group.
- Although survival comparisons across trials are difficult to interpret, this observation does appear to support idea that ruxolitinib may be modifying the natural history of primary myelofibrosis. |
